Polymer microspheres can be easily injected into the brain to provide a local and sustained delivery of chemotherapeutics to a tumor or surrounding tissue subject to high rates of tumor recurrence following surgery. Building on previous studies that established the clear advantage of local, peritumoral injections of sustained release microspheres, the following experiments utilized two different approaches for maximizing the survival benefit in glioma-bearing rats. In the first experiment, a previously grown cortical tumor was debulked and animals received either one or two treatments with carboplatin-loaded microspheres (either 200 or 800 µg total carboplatin per treatment). In each case, the microspheres were injected along the perimeter of the resection cavity with each treatment separated by 20 days. Survival studies clearly demonstrated that two, temporally spaced injections were superior to a single series of injections. At the lowest dose tested (200 µg), median survival was increased an additional 40% over that in animals receiving one treatment. At the higher dose (800 µg), one third of the animals receiving two separate treatments were long-term survivors (>150 days) and showed complete eradication of the tumor on histological examination. In the second experiment, we directly compared the efficacy produced by sustained release carboplatin or 1,3-bis[2-chloroethyl]-1-nitrourea (BCNU) alone versus injecting carboplatin and BCNU-loaded microspheres blended together as a single suspension. Carboplatin and BCNU both enhanced survival, with BCNU being significantly less effective than carboplatin. However, the greatest improvements in survival were seen when a blended suspension of carboplatin and BCNU microspheres was injected around the surgical cavity. In contrast, spatially alternating injections of BCNU and carboplatin microspheres was significantly less effective and the increase in survival was no greater than that achieved with BCNU alone. These data offer further support for the potential utility of local, sustained release chemotherapeutic microspheres for treating glioma. Moreover, they suggest that injectable chemotherapeutic microspheres may offer important advantages by (a) permitting multiple, temporally spaced injections to be made, as needed, and (b) providing the opportunity to deliver combinations of several different efficacious drugs directly to the tumor site to enhance survival beyond what can be achieved with delivery of any single chemotherapeutic agent.
INTRODUCTION
Microspheres have been proven to be efficient delivery vehicles for a wide range of chemotherapeutic drugs and can be easily injected into virtually any site of the brain The treatment of malignant glioma is limited. Despite even the most aggressive combinations of surgery, radi-with minimal invasiveness (6) . Using a rodent model of surgically resected glioma, ation therapy, and systemic chemotherapy, the median survival of patients is approximately 1 year from the we previously explored the possibility that chemotherapeutic microspheres could be injected into the tissue sur-time of diagnosis (1) . Biodegradable polymers might be used to improve the treatment of glioma by provid-rounding surgically resected glioma to selectively target the area where tumor infiltration is most likely to occur ing local and sustained delivery of chemotherapeutics (2-5, 7,8,10,11,13,14,16-18,21,23,24) . Polymers such (7, 9) . Direct injections of carboplatin and 1,3-bis[2-chloroethyl]-1-nitrourea (BCNU)-loaded microspheres into as poly(L-lactide)co-glycolide) (PLG) can be fabricated into small diameter, easily injectable microspheres with the tissue surrounding the surgical cavity produced significantly greater improvements in survival than were excellent release characteristics providing sustained delivery ranging from days to months (2, 7, 8, 10, (13) (14) (15) (16) (17) (18) .
achieved when the same microspheres were injected into the surgical cavity itself (7) . Subsequent studies con-of PLG was dissolved in 10 ml of methylene chloride. Ground/sieved carboplatin (110 ml) (<5 µm diameter) firmed and extended these results while providing insight into several of the principles required for the effi-was added to this solution and sonicated for 5 min followed by vigorous vortexing. Nine milliliters of poly(di-cacious use of chemotherapeutic microspheres (9) . These include the observations that: (a) an optimal dose of sus-methylsiloxane) (Aldrich, 350 cst) was then added and the resulting emulsion was mixed and stirred with 1 L tained release chemotherapy exists for enhancing efficacy, beyond which the local toxic effects can obviate of heptane for 2 h. The microspheres were collected by filtration and the solvent was allowed to evaporate. The the benefits of local delivery, (b) approximately 40% of the tissue surrounding the tumor resection cavity re-microspheres were then washed twice with 0.8% Triton X-100, suspended in a 1% polyvinyl acetate (PVA) solu-quires exposure to the chemotherapeutic to produce efficacy, and (c) the spatial distribution of the microsphere tion and sieved through 70-and 40-µM cell strainers. BCNU-loaded (Sigma Chemical) microspheres were fab-injections along the tumor perimeter greatly effects efficacy, requiring that no major gaps exist in the perimeter ricated by a solvent evaporation process. One gram of PLG and 110 mg of BCNU were dissolved in 7.5 ml of exposed to the chemotherapeutic agent.
Together, these data further support the potential of methylene chloride. The solution was added to a 100-ml 4-neck glass reaction flask containing 40 ml of 0.75% chemotherapeutic microspheres for the treatment of glioma, while suggesting that careful attention must be paid PVA. The organic phase was dispersed in aqueous medium and maintained at room temperature for 10 min to several fundamental principles in continued efforts to develop this approach. In the present studies, we exam-prior to being gradually raised to 40°C over 50 min. The solution was then maintained at 40°C for an additional ine two potential approaches that take advantage of the unique characteristics of chemotherapeutic microspheres. 50 min before cooling to room temperature and collecting the microspheres by filtration. All microspheres were First, we explore the possibility that multiple, temporally spaced microsphere injections might be more effi-washed with distilled water prior to being frozen at −70°C and lyophilized under 50 µTorr for 2 days. Blank cacious than a single treatment. Second, we exploit the ability to easily formulate a wide range of chemothera-(nonloaded) microspheres were treated in an identical manner except that carboplatin or BCNU was omitted peutics and simultaneously deliver multiple chemotherapeutics to the same sites by injecting a blend of micro-from the procedure. spheres containing two different chemotherapeutic agents.
Tumor Cell Implantation
MATERIALS AND METHODS
Rat glioma (RG2) cells were maintained and prepared Subjects for implantation as previously described. Rats were anesthetized with an intramuscular injection of ketamine (33 Male Fischer rats (N = 300; 200-220 g; Taconic mg/ml), xylazine (10 mg/ml), and acepromazine (1.6 Farms, Germantown, NY) were used in all studies. The mg/ml) and placed in a stereotaxic instrument. Using rats were housed in pairs in polypropylene cages with a 10-µl Hamilton syringe and a 22-gauge needle, cells free access to food and water. The vivarium was main-(5 × 10 4 cells/2 µl) were injected unilaterally into the tained on a 12-h light/12-h dark cycle with a room temcortex at the following coordinates: A-P (−1.0 mm), L perature of 22 ± 1°C and relative humidity level of 50 ± (+4.0 mm), and V (−2.5 mm) (19). 5%. All studies were approved in advance by Alkermes Institutional Animal Care and Use Committee and were Tumor Resection and Microsphere Implantation conducted in compliance with the rules set forth in the Fourteen days following implantation of RG2 cells, Guide for the Care and Use of Laboratory Animals.
anesthetized animals were placed into a stereotaxic de-Fabrication of Carboplatinvice and a craniotomy was made extending 2-4 mm raand BCNU-Loaded Microspheres dially from the original burr hole. The dura was excised and a hand-held aspirative device was used to grossly The chemotherapeutic microspheres used in these studies were the same as those previously described (7,8, resect the tumor from the cavity, leaving behind a small margin-positive resection area (approximately 10% of 10) and provided a sustained delivery of either carboplatin or BCNU for approximately 2-3 weeks. Briefly, micro-the original tumor mass) to evaluate the effects of the drug-loaded microspheres on regrowth of the tumor and spheres (PLG, Microsorb 50/50 DL, MW = 10 kDa, Alkermes Inc., Wilmington, OH) were fabricated to pro-survival of the animals. For implantation, the microspheres were suspended in a solution of 0.9% saline, vide a carboplatin loading density of 10% (w/w) and a BCNU loading density of 15% (w/w). Carboplatin-loaded 0.1% Tween, and 3.0% carboxymethylcellulose (low viscosity). The microsphere suspension (10 µl) was injected (Sigma Chemical, St. Louis, MO) microspheres were fabricated using a coacervation process. Initially, 1.0 g at a rate of 2 µl/min using a 10-µl Hamilton syringe with an attached 23-gauge needle. In all cases, the micro-either drug used alone. Animals received cortical implants of RG2 cells followed by debulking of the tumor spheres were injected approximately 1.0 mm from the edge of the resection cavity. Identical amounts of micro-14 days later and were assigned to one of several treatment groups (N = 15/group): surgical resection only, spheres were implanted in all cases by adding blank microspheres to the suspension. Animals were monitored surgical resection plus sustained release carboplatin (either 100 or 200 µg/site for a total of 800 or 1600 µg of daily, and any animal showing signs of morbidity was euthanized and that date recorded for calculating sur-carboplatin) injected into eight sites along the perimeter of the cavity, surgical resection plus sustained release vival data. BCNU (either 100 or 200 µg/site for a total of 800 or Effects of Repeated Carboplatin Microsphere 1600 µg of BCNU) injected into eight sites along the Injections on Survival perimeter of the cavity, or BCNU-loaded microspheres One hundred and twenty animals were used to commixed with carboplatin-loaded microspheres (100 µg of pare the efficacy produced by a single carboplatin micarboplatin plus 100 µg of BCNU/site for a total of 1600 crosphere injection versus two injections that were iden-µg of total drug). In the first experiment, coadministratical but separated by 20 days. Separate experiments tion of BCNU-and carboplatin-loaded microspheres were conducted examining the effects of two doses of was accomplished by blending the microspheres prior to sustained release carboplatin (either 25 or 100 µg/site).
suspending them. The blended mixture was then injected These doses were chosen based on previous dose-response using the techniques outline above. data demonstrating that these doses bracketed the range In a second experiment, direct comparisons were of enhanced survival produced by sustained release carmade between the efficacy produced by blending and boplatin. As previously shown, the lower dose (25 µg/ injecting carboplatin and BCNU microspheres versus alsite) produced significant but suboptimal increases in ternating injections of individual suspensions of carsurvival while the higher dose (100 µg/site) produced boplatin and BCNU microspheres. Following resection the greatest improvements in survival without encounof the tumor, animals were assigned to one of several tering toxic side effects. Animals received intracortical groups: surgical resection only, surgical resection plus implants of RG2 cells, followed by debulking of the tublended carboplatin and BCNU microspheres (50 or 100 mor 14 days later, and were divided into four treatment µg/site of each providing a total of either 800 or 1600 groups (N = 15/group): no resection/no resection/no treat-µg total drug), or surgical resection plus alternating inment, surgical resection only, surgical resection plus a jections of carboplatin and BCNU microspheres (100 or one-time injection of microspheres at the time of surgi-200 µg/site for a total of 800 or 1600 µg total drug). cal resection, and surgical resection plus a first injection of microspheres at the time of resection and a second, Histology identical treatment, 20 days later. This time point was Animals that were long-term survivors were transchosen for two reasons: (1) the previous survival studies cardially perfused under deep anesthesia using a perirevealed that this point represented a time at which anistaltic pump with 20 ml saline followed by 500 ml of mals were beginning to die but left a sample size large 4% Zamboni's fixative. All solutions were ice cold (4°C) enough for continued survival studies and (2) 20 days and prepared in 50 mM PBS (pH 7.4). Brains were reapproximates the maximum duration of carboplatin removed following fixation, placed in 25% buffered sulease, in vitro and in vivo, from the present microsphere crose (pH 7.4), and refrigerated for approximately 48 h. formulation. For the first injection, animals received mi-Sections were cut at 40-µm intervals on a sliding microcrospheres releasing 25 or 100 µg of carboplatin into tome and stored in a cryoprotectant solution. Every sixth each of eight separate sites (each 2 mm apart). For the section through the resection cavity was stained for hesecond treatment (20 days later), identical injections matoxylin and eosin (H&E). were made in between the original injection sites. In this way, the distribution of the injections remained constant Statistical Analysis while allowing the second injections to preferentially target the areas adjacent to the initial injections, where Survival after each treatment was analyzed using regrowth would be most likely to occur.
Kaplan-Meier survival curves. Nonparametric Kruskal-Wallis statistics were used to determine overall treat-Combined Carboplatin and BCNU Delivery ment effects using the day of death as the nonparametric From Microspheres variable (JMP, SAS Institute Inc., Cary, N.C.). The nonparametric modification of the Newman-Keuls test was One hundred and eighty animals were used to determine if the combination of sustained release carboplatin used for subsequent pairwise comparisons. Statistical significance in all cases was defined as p < 0.05. and BCNU enhances survival to a greater extent than
RESULTS
stained sections from these animals revealed that the tumor had been completely eradicated by the double injec-Effects of Repeated Carboplatin tion of sustained release carboplatin.
Microsphere Injections
Effects of Combining Carboplatin and BCNU As shown in Figure 1 , a single injection of sustained release microspheres (25 µg/site for a total of 200 µg of Consistent with the above experiment, a dose of 100 µg/site (800 µg total) sustained release carboplatin sig-carboplatin) significantly improved both median (84%) and maximum survival (158%) relative to surgical resec-nificantly improved survival (median survival increased 90% and maximum survival increased 185%), relative tion only ( ps < 0.01). A second treatment, identical to the first but 20 days later, further improved survival.
to surgery alone ( p < 0.001) ( Fig. 3) . Also in agreement with the previous experiments, increasing the carbo-These animals displayed median survival and maximum survival rates that were increased 158% and 253%, rela-platin dose from 100 to 200 µg/site obviated the beneficial effects of carboplatin producing median and maxi-tive to surgical resection only ( p < 0.001). The added improvement in survival afforded by a second treatment mum survival rates less than animals receiving surgery alone (decreased 40%, p < 0.05). Both doses of sus-was manifest as significant increases in both median and maximum survival (40% and 37%, respectively) relative tained release BCNU (100 and 200 µg/site) produced significant ( p < 0.01) and comparable improvements in to a single treatment with chemotherapeutic microspheres ( p < 0.05 vs. one treatment). The benefits of repeated survival, although this effect was markedly less than that achieved with 100 µg/site of sustained release carbo-injections of chemotherapeutic microspheres became more obvious when a previously defined optimal dose platin. Markedly greater improvements in survival were obtained when the microspheres releasing BCNU and of carboplatin was used (100 µg/site for a total of 800 µg of carboplatin) (Fig. 2) . A single injection of micro-carboplatin were mixed together and injected as a single suspension. Animals in this group exhibited a 190% in-spheres increased median survival by 141% and maximum survival by 272% ( p < 0.001) over that seen with crease in median survival and a 270% increase in maximum survival over that achieved with surgery alone ( p < surgery alone. Two separate injections, again 20 days apart, further increased median survival to 219% over 0.001). This effect was achieved even though the total amount of chemotherapeutic drug (800 µg carboplatin + that seen with surgery alone while 33% (5/15) of these animals were long-term survivors (>150 days; p < 0.01 800 µg BCNU) delivered was equal to the high dose of carboplatin (1600 µg), which failed to enhance survival vs. a single treatment). Histological analysis of H+E- . Survival following higher doses (100 µg/site) of carboplatin, again using either a single treatment or two separate treatments separated by 20 days. The higher dose of sustained release carboplatin had previously been shown to optimally enhance survival in this model. While a single treatment significantly enhanced survival in this model, the effects were even more robust in the animals receiving two treatments, with one third of the animals surviving the duration of the experiment (150 days). Histological analysis verified that the tumors in these animals were completely eradicated by sustained release carboplatin. and the high dose of BCNU (1600 µg), which proved treatments, or equivalent doses of systemic chemotherapy. Importantly, sustained release chemotherapy was no better than the low dose of BCNU (800 µg).
A separate experiment replicated and extended these significantly more effective when the microspheres were placed directly into the brain tissue surrounding a de-results by directly comparing the efficacy produced by blending and injecting carboplatin and BCNU micro-bulked tumor as opposed to the surgical resection cavity itself (7) . Similarly, in a model of inoperative glioma, sus-spheres as a single suspension versus spatially alternating injections of each formulation (Fig. 4 ). Relative to tained release microspheres proved much more effective when injected into the surrounding peritumoral brain tis-surgery alone, median survival was enhanced 55-77% and maximum survival was enhanced 61-70% ( ps < 0.01) sue than when injected directly into the tumor (8) .
Because microsphere injections can be made using a when the carboplatin and BCNU microspheres were injected into spatially alternating sites (800 and 1600 µg standard hypodermic needle with minimal invasiveness to the injected tissue (6), repeated, temporally spaced in-of total drug, respectively). Consistent with the results of the previous study, median survival was enhanced jections into the tissue surrounding a debulked tumor are possible. The present studies examined the survival 193-245% and maximum survival was enhanced 250-283% when the microspheres were blended together and benefits produced by treating animals either once or twice, separated by 20 days. Using an effective, but sub-injected into each site ( ps < 0.001).
optimal dose of sustained release carboplatin, a single DISCUSSION treatment with carboplatin microspheres significantly enhanced survival. However, animals receiving two tem-Given the fatal nature of glioma, numerous recent attempts have been made to improve upon the efficacy of porally spaced treatments exhibited survival that was enhanced an additional 40% beyond that obtained with a currently available chemotherapeutic treatments. Using a novel rodent model of surgically resected glioma, we single treatment. Even more benefit of multiple, temporally spaced treatments was seen when the dose of car-previously reported that local injections of sustained release chemotherapeutic microspheres can significantly boplatin was increased to a previously defined optimal level. Not only was median survival enhanced nearly enhance survival over that achieved with local bolus Fig. 1) but not when the dose was increased to 200 µg/site. BCNU-loaded microspheres produced comparable increases in survival at both doses (100 or 200 µg/site). Significantly greater increases in survival were produced by simultaneous, sustained delivery of both carboplatin and BCNU, even though the total dose was no higher than that used for the monotherapy groups.
300%, but one third of the animals became long-term
These data also demonstrate the unique ability of sustained release microspheres to provide simple, conve-survivors and, upon sacrifice, exhibited complete eradication of the tumor. nient, and potentially effective polypharmacy. In theory, many polymer-based systems could be used to deliver The results of these studies could have direct implications for the treatment of glioma. In clinical practice, two or more compounds by encapsulating the compounds within the same polymer. However, several practical is-recurrence of glioma typically occurs within 1-2 cm of the original debulked tumor. Unfortunately, repeated sues, including markedly different formulation parameters required for successful incorporation of different surgical debulking of recurring glioma is often not desirable due to the invasive nature of the surgery that drugs into polymers, stability of the drugs once encapsulated, and predictability of release rates, make this ap-invariably results in removal of healthy brain tissue surrounding the original resection cavity. Not only does proach difficult. In contrast, two or more different formulations, each containing different chemotherapeutics, significant neural trauma and neurological complications result, but the repeated surgery typically fails to produce can simply be mixed together and injected as a single suspension. In this case, different drugs would be re-any additional patient benefit (12). Injections of chemotherapeutic microspheres might present an alternative or leased individually from their respective microspheres and mixed together as they diffused into the surrounding adjunctive approach to conventional surgical debulking since treatments can be performed repeatedly, spaced tissue. Here we formulated microspheres to release either carboplatin or BCNU and injected them alone or in several weeks to months apart. Using standard imaging techniques, it might be possible to identify small areas combination along the perimeter of the resection cavity. Both BCNU-and carboplatin-loaded microspheres en-with a high probability of tumor regrowth and selectively target those areas with additional chemotherapeu-hanced survival, although the magnitude of this effect was greater with carboplatin. Further increasing the dose tic microsphere injections, perhaps providing even greater opportunity for improved survival (20) .
of BCNU did not further improve survival, while increas- Figure 3 , survival was greatly enhanced under these conditions. Survival was modestly improved with spatially alternating injections of the different chemotherapeutic microspheres. Much more robust survival was achieved when the micropsheres were blended and injected together as a suspension into each site along the tumor margin. Together with the results shown in Figure 3 , these data clearly demonstrate the advantages of using multiple chemotherapeutic microspheres and the importance that the different drugs be delivered simultaneously into the same target regions.
ing the dose of carboplatin to 200 µg/site actually de-over the past 10 years suggest that injectable biodegradeable polymers releasing chemotherapeutic agents creased survival from that achieved with surgery alone. These data clearly demonstrate the limitations of simply could have significant clinical value in the treatment of glioma (10). Polymer microspheres have several unique increasing local concentrations of a single chemotherapeutic agent. In contrast, however, profound and reliable characteristics that make them particularly appealing, relative to other, larger implantable delivery systems (9, improvements in survival were obtained when microspheres releasing BCNU and carboplatin were mixed to-22), as a means of providing local, high, and sustained concentrations of therapeutic drugs to tumors. In partic-gether. Interestingly, this enhanced effect was achieved even though the total amount of chemotherapeutic drug ular, they can be injected into virtually any brain region, with minimal invasiveness, to provide very precise and (carboplatin + BCNU) delivered was equal to the high dose of carboplatin, which had caused a decrease in sur-controlled delivery for days to months. Our prior research demonstrated that injections of chemotherapeutic micro-vival. Moreover, it was also shown that blending and injecting the mixture of chemotherapeutic microspheres spheres into peritumoral brain areas offer far greater efficacy than equivalent injections into the tumor or the cav-into each injection site was required to provide enhanced benefit. For example, when the BCNU and carboplatin ity formed by surgical resection of the tumor (7, 8) . Thus, chemotherapeutic microspheres offer an important ad-microspheres were injected separately, into spatially alternating sites along the tumor margin, the benefits were vantage by being able to selectively target areas of high tumor recurrence. The present experiments demonstrate no greater than those produced by BCNU-loaded microspheres alone. even greater efficacy when the microspheres are injected over several, termporally spaced treatments, represent-In conclusion, several convergent lines of evidence cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery 39:1191-
